An Endophenotype Network Strategy Uncovers YangXue QingNao Wan Suppresses Aβ Deposition, Improves Mitochondrial Dysfunction and Glucose Metabolism

Alzheimer's disease (AD), an escalating global health issue, lacks effective treatments due to its complex pathogenesis. YangXue QingNao Wan (YXQNW) is a China Food and Drug Administration (CFDA)- approved TCM formula that has been repurposed in clinical Phase II for the treatment of AD. Identifying YXQNW's active ingredients and their mechanisms is crucial for developing effective AD treatments.